Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors - PubMed (original) (raw)

Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors

N Boulle et al. J Clin Endocrinol Metab. 1998 May.

Abstract

In adrenocortical tumors, malignancy is strongly associated with insulin-like growth factor II (IGF-II) gene overexpression and abnormalities at the 11p15 locus, suggesting a role for this growth factor in adrenocortical tumorigenesis. To further investigate this role, the IGF/IGF-binding protein (IGFBP) system was analyzed in 18 adrenocortical tumors, classified into 2 groups on the basis of their IGF-II messenger ribonucleic acid (mRNA) content (group 1, normal IGF-II mRNA content, mostly benign tumors; group 2, high IGF-II mRNA content, mostly malignant tumors). Group 2 tumors contained 10 times more IGF-II protein than group 1 tumors or normal adrenal tissue (P < 0.001), indicating efficient translation of IGF-II mRNA in malignant tumors. Western ligand blotting detected various functional IGFBPs in normal adrenocortical glands and tumors: a doublet of 39-42 kDa identified by immunoblotting as IGFBP-3, a band at 32 kDa, and bands at 29-30 and 24 kDa. Total IGFBP-3 protein levels were similar in the two groups of tumors. By contrast, malignant tumors differed from benign ones by specific expression of the 32-kDa IGFBP. Immunoblotting identified this 32-kDa band together with a proteolytic fragment of 25 kDa as IGFBP-2, and quantitative analysis showed significantly higher levels of total IGFBP-2 in malignant tumors than in benign tumors (P < 0.001). Despite enhanced levels of IGBP-2 protein in malignant tumors, no increase in IGFBP-2 mRNA levels was detected, suggesting post-transcriptional regulation of this IGFBP. These results confirm the major role of IGF-II in adrenocortical tumorigenesis and suggest that IGFBP-2 may be a regulator of IGF-II proliferative effects in this tumor system.

PubMed Disclaimer

Cited by

Altered expression of the IGF2‑H19 locus and mitochondrial respiratory complexes in adrenocortical carcinoma.
Scicluna P, Caramuta S, Kjellin H, Xu C, Fröbom R, Akhtar M, Gao J, Shi H, Kjellman M, Almgren M, Höög A, Zedenius J, Ekström TJ, Bränström R, Lui WO, Larsson C. Scicluna P, et al. Int J Oncol. 2022 Nov;61(5):140. doi: 10.3892/ijo.2022.5430. Epub 2022 Sep 28. Int J Oncol. 2022. PMID: 36169175 Free PMC article.
MDA-9/syntenin and IGFBP-2 promote angiogenesis in human melanoma.
Das SK, Bhutia SK, Azab B, Kegelman TP, Peachy L, Santhekadur PK, Dasgupta S, Dash R, Dent P, Grant S, Emdad L, Pellecchia M, Sarkar D, Fisher PB. Das SK, et al. Cancer Res. 2013 Jan 15;73(2):844-54. doi: 10.1158/0008-5472.CAN-12-1681. Epub 2012 Dec 10. Cancer Res. 2013. PMID: 23233738 Free PMC article.
Chloroquine alleviates etoposide-induced centrosome amplification by inhibiting CDK2 in adrenocortical tumor cells.
Chen TY, Syu JS, Lin TC, Cheng HL, Lu FL, Wang CY. Chen TY, et al. Oncogenesis. 2015 Dec 21;4(12):e180. doi: 10.1038/oncsis.2015.37. Oncogenesis. 2015. PMID: 26690546 Free PMC article.
Analysis of the role of Igf2 in adrenal tumour development in transgenic mouse models.
Drelon C, Berthon A, Ragazzon B, Tissier F, Bandiera R, Sahut-Barnola I, de Joussineau C, Batisse-Lignier M, Lefrançois-Martinez AM, Bertherat J, Martinez A, Val P. Drelon C, et al. PLoS One. 2012;7(8):e44171. doi: 10.1371/journal.pone.0044171. Epub 2012 Aug 28. PLoS One. 2012. PMID: 22952916 Free PMC article.
Adrenocortical tumors and hyperplasias in childhood--etiology, genetics, clinical presentation and therapy.
Sutter JA, Grimberg A. Sutter JA, et al. Pediatr Endocrinol Rev. 2006 Sep;4(1):32-9. Pediatr Endocrinol Rev. 2006. PMID: 17021581 Free PMC article. Review.

Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors - PubMed (original) (raw)